Skip to main content
SpringerLink
Log in

Drug-Induced Thrombosis: An Update

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Drugs may play an important role in development of thrombosis, and in recent years there has been increased attention to the importance of this issue. Although drug-induced thrombosis usually causes venous thrombotic events, arterial events are also noted due to drug administration. Here we review the different mechanisms through which drugs can exert thrombosis. Drugs can cause direct endothelial damage and expose the underlying subendothelium thus leading to platelet adherence and subsequent thrombus formation. Such an effect is seen by contrast media and chemotherapeutic cytotoxic drugs. Drugs may also attenuate the secretion of pro- and anticoagulation mediators by the endothelial cells and may have prothrombotic effects on platelets by increasing adhesion and aggregation, as for example seen after heparin administration in an immune-mediated mechanism. Red and white cells can also be affected by drugs, by increasing their aggregation or adhesion to the endothelial wall. Some drugs, such as oral contraceptive pills, may promote thrombosis by altering the balance between the different coagulation factors, and many drugs can lead to decreased blood flow by increasing blood viscosity, as seen for example after intravenous immunoglobulin administration. Better understanding of the mechanisms through which drugs exert thrombosis may facilitate their safe use in patients. Additionally, awareness of the drugs that are known to induce thrombosis is important in order to stop their administration in case of a thrombotic event. This review further emphasizes the fact that drug administration is a risk factor that should always be considered together with additional known thromboembolic risk factors such as genetic predisposition or cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Zbinden G. Evaluation of thrombogenic effects of drugs. Annu Rev Pharmacol Toxicol. 1976;16:177–88.

    Article  CAS  PubMed  Google Scholar 

  2. Kasliwal R, Layton D, Harris S, Wilton L, Shakir SA. A comparison of reported gastrointestinal and thromboembolic events between rofecoxib and celecoxib using observational data. Drug Saf. 2005;28(9):803–16.

    Article  CAS  PubMed  Google Scholar 

  3. Sachdeva R, Sivasankaran S, Fishman RF, Zarich SW, McPherson CA. Coronary thrombosis related to use of Xenadrine RFA. Tex Heart Inst J. 2005;32(1):74–7.

    PubMed  Google Scholar 

  4. Bennett CL, Angelotta C, Yarnold PR, Evens AM, Zonder JA, Raisch DW, et al. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer. JAMA. 2006;296(21):2558–60.

    Article  CAS  PubMed  Google Scholar 

  5. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med. 2007;356(24):2448–51.

    Article  CAS  PubMed  Google Scholar 

  6. Anderson FA, Jr., Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl. 1):I9–16.

    Google Scholar 

  7. Ramot Y, Nyska A. Drug-induced thrombosis: experimental, clinical, and mechanistic considerations. Toxicol Pathol. 2007;35(2):208–25.

    Article  CAS  PubMed  Google Scholar 

  8. Schultze AE, Walker DB, Turk JR, Tarrant JM, Brooks MB, Pettit SD. Current practices in preclinical drug development: gaps in hemostasis testing to assess risk of thromboembolic injury. Toxicol Pathol. 2013;41(3):445–53.

    Article  PubMed  Google Scholar 

  9. Blann AD, Lip GY. Virchow’s triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets. Thromb Res. 2001;101(4):321–7.

    Article  CAS  PubMed  Google Scholar 

  10. Slauson D, Cooper B. Mechanisms of disease: a textbook of comparative general pathology. 3rd ed. St. Louis: Mosby; 2002.

    Google Scholar 

  11. Blann AD. How a damaged blood vessel wall contributes to thrombosis and hypertension. Pathophysiol Haemost Thromb. 2003;33(5–6):445–8.

    Article  PubMed  Google Scholar 

  12. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008;117(11):1449–59.

    Article  CAS  PubMed  Google Scholar 

  13. Gorbet MB, Sefton MV. Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials. 2004;25(26):5681–703.

    Article  CAS  PubMed  Google Scholar 

  14. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11(2):178–89.

    Article  PubMed  Google Scholar 

  15. Longstaff C, Thelwell C. Understanding the enzymology of fibrinolysis and improving thrombolytic therapy. FEBS Lett. 2005;579(15):3303–9.

    Article  CAS  PubMed  Google Scholar 

  16. Lowe GD. Virchow’s triad revisited: abnormal flow. Pathophysiol Haemost Thromb. 2003;33(5–6):455–7.

    Article  PubMed  Google Scholar 

  17. Wootton DM, Ku DN. Fluid mechanics of vascular systems, diseases, and thrombosis. Annu Rev Biomed Eng. 1999;1:299–329.

    Article  CAS  PubMed  Google Scholar 

  18. Dormandy JA, Edelman JB. High blood viscosity: an aetiological factor in venous thrombosis. Br J Surg. 1973;60(3):187–90.

    Article  CAS  PubMed  Google Scholar 

  19. Kropelin T, Gospos C, Papacaralampous X, Freudenberg N. The risk liability of nephrotropic contrast media: clinical and experimental results. Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd. 1983;118:129–42.

    CAS  PubMed  Google Scholar 

  20. Palomaki H, Muuronen A, Raininko R, Piilonen A, Kaste M. Administration of nonionic iodinated contrast medium does not influence the outcome of patients with ischemic brain infarction. Cerebrovasc Dis. 2003;15(1–2):45–50.

    PubMed  Google Scholar 

  21. Raininko R. Morphologic endothelial response to meglumine diatrizoate: an electron-microscopic study. Angiology. 1981;32(11):733–41.

    Article  CAS  PubMed  Google Scholar 

  22. Aliev G, Obrenovich ME, Seyidova D, Rzayev NM, Aliyev AS, Raina AK, et al. X-ray contrast media induce aortic endothelial damage, which can be prevented with prior heparin treatment. J Submicrosc Cytol Pathol. 2003;35(3):253–66.

    CAS  PubMed  Google Scholar 

  23. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007–15.

    Article  PubMed  Google Scholar 

  24. Mare K, Violante M. Pulmonary edema induced by contrast medium: a comparative investigation in the rat following high intravenous doses of one ionic (diatrizoate) and non-ionic (metrizamide) contrast medium. Acta Radiol Diagn (Stockh). 1983;24(6):481–5.

    CAS  Google Scholar 

  25. Mare K, Violante M. Pulmonary edema induced by high intravenous doses of diatrizoate in the rat. Acta Radiol Diagn (Stockh). 1983;24(5):419–24.

    CAS  Google Scholar 

  26. Tsuda N. In situ quantification of endothelial cell damage caused by iodinated contrast media using a rat vena cava model. Eur J Radiol. 2012;81(5):879–84.

    Article  PubMed  Google Scholar 

  27. Gospos C, Freudenberg N, Staubesand J, Mathias K, Papacharlampos X. The effect of contrast media on the aortic endothelium of rats. Radiology. 1983;147(3):685–8.

    CAS  PubMed  Google Scholar 

  28. Gospos C, Koch HK, Mathias K, Seemann W, Tan KG, Papacharalampous X. Scanning electron microscopic (SEM) studies on the effect of x-ray contrast media on aortic endothelium in the rat. Invest Radiol. 1983;18(4):382–6.

    Article  CAS  PubMed  Google Scholar 

  29. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 2003;42(4):304–8.

    Article  CAS  PubMed  Google Scholar 

  30. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem. 2006;4(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  31. van Heeckeren WJ, Sanborn SL, Narayan A, Cooney MM, McCrae KR, Schmaier AH, et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol. 2007;14(5):468–80.

    Article  PubMed  Google Scholar 

  32. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28(11):1779–802.

    Article  CAS  PubMed  Google Scholar 

  33. Zakarija A, Kwaan HC. Adverse effects on hemostatic function of drugs used in hematologic malignancies. Semin Thromb Hemost. 2007;33(4):355–64.

    Article  CAS  PubMed  Google Scholar 

  34. Carneiro AM, Barthelmes D, Falcao MS, Mendonca LS, Fonseca SL, Goncalves RM, et al. Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011;225(4):211–21.

    Article  CAS  PubMed  Google Scholar 

  35. Sartelet H, Toupance O, Lorenzato M, Fadel F, Noel LH, Lagonotte E, et al. Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys. Am J Transplant. 2005;5(10):2441–7.

    Article  PubMed  Google Scholar 

  36. Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Expert Opin Biol Ther. 2008;8(4):527–40.

    Article  CAS  PubMed  Google Scholar 

  37. Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.

    Article  CAS  PubMed  Google Scholar 

  38. Favaloro EJ. Differential expression of surface antigens on activated endothelium. Immunol Cell Biol. 1993;71(Pt 6):571–81.

    Article  CAS  PubMed  Google Scholar 

  39. Brisse H, Orbach D, Lassau N, Servois V, Doz F, Debray D, et al. Portal vein thrombosis during antineoplastic chemotherapy in children: report of five cases and review of the literature. Eur J Cancer. 2004;40(18):2659–66.

    Article  CAS  PubMed  Google Scholar 

  40. Caine GJ, Stonelake PS, Rea D, Lip GY. Coagulopathic complications in breast cancer. Cancer. 2003;98(8):1578–86.

    Article  PubMed  Google Scholar 

  41. Venkatraman S, Boey F. Release profiles in drug-eluting stents: issues and uncertainties. J Control Release. 2007;120(3):149–60.

    Article  CAS  PubMed  Google Scholar 

  42. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116(17):1952–65.

    Article  PubMed  Google Scholar 

  43. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701–5.

    Article  PubMed  Google Scholar 

  44. Jen CJ, Dong HP, Chen H, Wing LC, Tang MJ, Chang WC, et al. Platelet adhesion following the administration of tissue-type plasminogen activator and its reversal by vitamin E in rats. Thromb Haemost. 1996;75(1):101–6.

    CAS  PubMed  Google Scholar 

  45. Van de Werf FJ, Topol EJ, Sobel BE. The impact of fibrinolytic therapy for ST-segment-elevation acute myocardial infarction. J Thromb Haemost. 2009;7(1):14–20.

    Article  PubMed  CAS  Google Scholar 

  46. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.

    Article  CAS  PubMed  Google Scholar 

  47. Parikh S, Motarjeme A, McNamara T, Raabe R, Hagspiel K, Benenati JF, et al. Ultrasound-accelerated thrombolysis for the treatment of deep vein thrombosis: initial clinical experience. J Vasc Interv Radiol. 2008;19(4):521–8.

    Article  PubMed  Google Scholar 

  48. Doepp F, Sanad W, Schreiber SJ, Baumann G, Borges AC. Left ventricular apical thrombus after systemic thrombolysis with recombinant tissue plasminogen activator in a patient with acute ischemic stroke. Cardiovasc Ultrasound. 2005;3:14.

    Article  PubMed  Google Scholar 

  49. Fassbender K, Dempfle CE, Mielke O, Schwartz A, Daffertshofer M, Eschenfelder C, et al. Changes in coagulation and fibrinolysis markers in acute ischemic stroke treated with recombinant tissue plasminogen activator. Stroke. 1999;30(10):2101–4.

    Article  CAS  PubMed  Google Scholar 

  50. Conforti G, Dominguez-Jimenez C, Ronne E, Hoyer-Hansen G, Dejana E. Cell-surface plasminogen activation causes a retraction of in vitro cultured human umbilical vein endothelial cell monolayer. Blood. 1994;83(4):994–1005.

    CAS  PubMed  Google Scholar 

  51. Shi GY, Hau JS, Wang SJ, Wu IS, Chang BI, Lin MT, et al. Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells. J Biol Chem. 1992;267(27):19363–8.

    CAS  PubMed  Google Scholar 

  52. Bombeli T, Muller M, Straub PW, Haeberli A. Cyclosporine-induced detachment of vascular endothelial cells initiates the intrinsic coagulation system in plasma and whole blood. J Lab Clin Med. 1996;127(6):621–34.

    Article  CAS  PubMed  Google Scholar 

  53. Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors: a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost. 1996;75(2):368–71.

    CAS  PubMed  Google Scholar 

  54. Tolcher AW, Giusti RM, O’Shaughnessy JA, Cowan KH. Arterial thrombosis associated with granulocyte-macrophage colony-stimulating factor (GM-CSF) administration in breast cancer patients treated with dose-intensive chemotherapy: a report of two cases. Cancer Invest. 1995;13(2):188–92.

    Article  CAS  PubMed  Google Scholar 

  55. de Vries EG, Willemse PH, Biesma B, Stern AC, Limburg PC, Vellenga E. Flare-up of rheumatoid arthritis during GM-CSF treatment after chemotherapy. Lancet. 1991;338(8765):517–8.

    Article  PubMed  Google Scholar 

  56. Stehle B, Weiss C, Ho AD, Hunstein W. Serum levels of tumor necrosis factor alpha in patients treated with granulocyte-macrophage colony-stimulating factor. Blood. 1990;75(9):1895–6.

    CAS  PubMed  Google Scholar 

  57. Pogrebniak HW, Matthews W, Pass HI. Chemotherapy amplifies production of tumor necrosis factor. Surgery. 1991;110(2):231–7.

    CAS  PubMed  Google Scholar 

  58. Micallef M. Immunoregulatory cytokine production by tumor-bearing rat spleen cells and its modulation by bleomycin. Anticancer Drugs. 1993;4(2):213–22.

    Article  CAS  PubMed  Google Scholar 

  59. Gerl A. Vascular toxicity associated with chemotherapy for testicular cancer. Anticancer Drugs. 1994;5(6):607–14.

    Article  CAS  PubMed  Google Scholar 

  60. Nemerson Y. Tissue factor and hemostasis. Blood. 1988;71(1):1–8.

    CAS  PubMed  Google Scholar 

  61. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant. 2004;33(2):171–6.

    Article  CAS  PubMed  Google Scholar 

  62. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med. 2002;8(2):128–35.

    Article  CAS  PubMed  Google Scholar 

  63. Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, et al. Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood. 2005;105(11):4463–9.

    Article  CAS  PubMed  Google Scholar 

  64. Vane J. Towards a better aspirin. Nature. 1994;367(6460):215–6.

    Article  CAS  PubMed  Google Scholar 

  65. US FDA. FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product, 30 Sep 2004. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2004/ucm108361.htm. Accessed 12 April 2013.

  66. Krotz F, Schiele TM, Klauss V, Sohn HY. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res. 2005;42(4):312–24.

    Article  PubMed  CAS  Google Scholar 

  67. Toborek M, Kaiser S. Endothelial cell functions: relationship to atherogenesis. Basic Res Cardiol. 1999;94(5):295–314.

    Article  CAS  PubMed  Google Scholar 

  68. Meyer CH, Schmidt JC, Rodrigues EB, Mennel S. Risk of retinal vein occlusions in patients treated with rofecoxib (vioxx). Ophthalmologica. 2005;219(4):243–7.

    Article  CAS  PubMed  Google Scholar 

  69. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–8.

    Article  CAS  PubMed  Google Scholar 

  70. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(3 Suppl.):234S–64S.

    Google Scholar 

  71. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl.):e637–68S.

    Google Scholar 

  72. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71(3):676–88.

    Article  CAS  PubMed  Google Scholar 

  73. Duperray A, Tranqui L, Alix JL, Cordonnier D. Effect of mitomycin C on prostacyclin synthesis by human endothelial cells. Biochem Pharmacol. 1988;37(24):4753–7.

    Article  CAS  PubMed  Google Scholar 

  74. Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 1996;50(4):1255–61.

    Article  CAS  PubMed  Google Scholar 

  75. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33(5):821–8.

    Article  CAS  PubMed  Google Scholar 

  76. Woodley-Cook J, Shin LY, Swystun L, Caruso S, Beaudin S, Liaw PC. Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. Mol Cancer Ther. 2006;5(12):3303–11.

    Article  CAS  PubMed  Google Scholar 

  77. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–71.

    Article  CAS  PubMed  Google Scholar 

  78. Corso A, Lorenzi A, Terulla V, Airo F, Varettoni M, Mangiacavalli S, et al. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone. Ann Hematol. 2004;83(9):588–91.

    Article  CAS  PubMed  Google Scholar 

  79. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103(6):879–87.

    Article  CAS  PubMed  Google Scholar 

  80. Kaushal V, Kaushal GP, Melkaveri SN, Mehta P. Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology. J Thromb Haemost. 2004;2(2):327–34.

    Article  CAS  PubMed  Google Scholar 

  81. Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the second Princeton consensus conference). Am J Cardiol. 2005;96(2):313–21.

    Article  PubMed  Google Scholar 

  82. McGwin G Jr, Vaphiades MS, Hall TA, Owsley C. Non-artheritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol. 2006;90(2):154–7.

    Article  PubMed  Google Scholar 

  83. Tripathi A, O’Donnell NP. Branch retinal artery occlusion; another complication of sildenafil. Br J Ophthalmol. 2000;84(8):934–5.

    Article  CAS  PubMed  Google Scholar 

  84. Arora RR, Timoney M, Melilli L. Acute myocardial infarction after the use of sildenafil. N Engl J Med. 1999;341(9):700.

    Article  CAS  PubMed  Google Scholar 

  85. Morgan JC, Alhatou M, Oberlies J, Johnston KC. Transient ischemic attack and stroke associated with sildenafil (Viagra) use. Neurology. 2001;57(9):1730–1.

    Article  CAS  PubMed  Google Scholar 

  86. Rufa A, Cerase A, Monti L, Dotti MT, Giorgio A, Sicurelli F, et al. Recurrent venous thrombosis including cerebral venous sinus thrombosis in a patient taking sildenafil for erectile dysfunction. J Neurol Sci. 2007;260(1–2):293–5.

    Article  CAS  PubMed  Google Scholar 

  87. Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol. 2002;39(4–5):213–23.

    Article  CAS  PubMed  Google Scholar 

  88. Blank M, Shoenfeld Y, Tavor S, Praprotnik S, Boffa MC, Weksler B, et al. Anti-platelet factor 4/heparin antibodies from patients with heparin-induced thrombocytopenia provoke direct activation of microvascular endothelial cells. Int Immunol. 2002;14(2):121–9.

    Article  CAS  PubMed  Google Scholar 

  89. Reilly MP, McKenzie SE. Insights from mouse models of heparin-induced thrombocytopenia and thrombosis. Curr Opin Hematol. 2002;9(5):395–400.

    Article  PubMed  Google Scholar 

  90. Bennett CL, Kim B, Zakarija A, Bandarenko N, Pandey DK, Buffie CG, et al. Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project. J Am Coll Cardiol. 2007;50(12):1138–43.

    Article  CAS  PubMed  Google Scholar 

  91. Franchini M, Montagnana M, Targher G, Lippi G. Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. Semin Thromb Hemost. 2007;33(8):787–97.

    Article  CAS  PubMed  Google Scholar 

  92. Mannucci PM. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome: much progress and many remaining issues. Haematologica. 2007;92(7):878–80.

    Article  PubMed  Google Scholar 

  93. Andersohn F, Bronder E, Klimpel A, Garbe E. Proportion of drug-related serious rare blood dyscrasias: estimates from the Berlin Case–Control Surveillance Study. Am J Hematol. 2004;77(3):316–8.

    Article  PubMed  Google Scholar 

  94. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol. 2001;8(5):286–93.

    Article  CAS  PubMed  Google Scholar 

  95. Dlott JS, Danielson CF, Blue-Hnidy DE, McCarthy LJ. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Ther Apher Dial. 2004;8(2):102–11.

    Article  CAS  PubMed  Google Scholar 

  96. Murgo AJ. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents. Semin Hematol. 1987;24(3):161–77.

    CAS  PubMed  Google Scholar 

  97. Aguejouf O, Malfatti E, Doutremepuich F, Doutremepuich C. Thrombogenic potential of contrast media in an experimental model of laser-induced thrombosis. Thromb Res. 2000;100(3):167–77.

    Article  CAS  PubMed  Google Scholar 

  98. Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer. 2003;98(7):1514–20.

    Article  CAS  PubMed  Google Scholar 

  99. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood. 1991;78(1):154–62.

    CAS  PubMed  Google Scholar 

  100. Wun T, Paglieroni T, Hammond WP, Kaushansky K, Foster DC. Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. Am J Hematol. 1997;54(3):225–32.

    Article  CAS  PubMed  Google Scholar 

  101. Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood. 2000;95(9):2983–9.

    CAS  PubMed  Google Scholar 

  102. Maly R, Masopust J, Hosak L, Konupcikova K. Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci. 2008;62(1):3–8.

    Article  PubMed  Google Scholar 

  103. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104(16):1894–8.

    Article  CAS  PubMed  Google Scholar 

  104. Kurne A, Ertugrul A, Anil Yagcioglu AE, Yazici KM. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry. 2004;26(6):481–3.

    Article  PubMed  Google Scholar 

  105. Hagg S, Spigset O. Antipsychotic-induced venous thromboembolism: a review of the evidence. CNS Drugs. 2002;16(11):765–76.

    Article  PubMed  Google Scholar 

  106. Axelsson S, Hagg S, Eriksson AC, Lindahl TL, Whiss PA. In vitro effects of antipsychotics on human platelet adhesion and aggregation and plasma coagulation. Clin Exp Pharmacol Physiol. 2007;34(8):775–80.

    Article  CAS  PubMed  Google Scholar 

  107. Hagg S, Bate A, Stahl M, Spigset O. Associations between venous thromboembolism and antipsychotics: a study of the WHO database of adverse drug reactions. Drug Saf. 2008;31(8):685–94.

    Article  PubMed  Google Scholar 

  108. Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, Kontek B. The first- and second-generation antipsychotic drugs affect ADP-induced platelet aggregation. World J Biol Psychiatry. 2010;11(2 Pt 2):268–75.

    Article  PubMed  Google Scholar 

  109. Dietrich-Muszalska A, Rabe-Jablonska J, Olas B. The effects of the second generation antipsychotics and a typical neuroleptic on collagen-induced platelet aggregation in vitro. World J Biol Psychiatry. 2010;11(2 Pt 2):293–9.

    Article  PubMed  Google Scholar 

  110. Wallaschofski H, Eigenthaler M, Kiefer M, Donne M, Hentschel B, Gertz HJ, et al. Hyperprolactinemia in patients on antipsychotic drugs causes ADP-stimulated platelet activation that might explain the increased risk for venous thromboembolism: pilot study. J Clin Psychopharmacol. 2003;23(5):479–83.

    Article  CAS  PubMed  Google Scholar 

  111. Reuwer AQ, Nieuwland R, Fernandez I, Goffin V, van Tiel CM, Schaap MC, et al. Prolactin does not affect human platelet aggregation or secretion. Thromb Haemost. 2009;101(6):1119–27.

    CAS  PubMed  Google Scholar 

  112. Al-Shekhlee A, Oghlakian G, Katirji B. A case of cyclosporine-induced dural sinus thrombosis. J Thromb Haemost. 2005;3(6):1327–8.

    Article  CAS  PubMed  Google Scholar 

  113. Fishman SJ, Wylonis LJ, Glickman JD, Cook JJ, Warsaw DS, Fisher CA, et al. Cyclosporin A augments human platelet sensitivity to aggregating agents by increasing fibrinogen receptor availability. J Surg Res. 1991;51(2):93–8.

    Article  CAS  PubMed  Google Scholar 

  114. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146(6):882–93.

    Article  CAS  PubMed  Google Scholar 

  115. Ramot Y, Steiner M, Morad V, Leibovitch S, Amouyal N, Cesta MF, et al. Pulmonary thrombosis in the mouse following intravenous administration of quantum dot-labeled mesenchymal cells. Nanotoxicology. 2010;4(1):98–105.

    Article  CAS  PubMed  Google Scholar 

  116. Ajzenberg N, Aubry P, Huisse MG, Cachier A, El Amara W, Feldman LJ, et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol. 2005;45(11):1753–6.

    Article  PubMed  Google Scholar 

  117. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120(22):2271–306.

    Article  PubMed  Google Scholar 

  118. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol. 1999;6(2):76–82.

    Article  CAS  PubMed  Google Scholar 

  119. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 1997;89(4):1121–32.

    CAS  PubMed  Google Scholar 

  120. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci. 2005;62(9):971–88.

    Article  CAS  PubMed  Google Scholar 

  121. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol. 1999;107(2):300–2.

    Article  CAS  PubMed  Google Scholar 

  122. Brown G, Giffin H. The treatment of polycytemia with phenylhydrazine. Arch Int Med. 1926;38:321.

    Article  CAS  Google Scholar 

  123. Ramot Y, Koshkaryev A, Goldfarb A, Yedgar S, Barshtein G. Phenylhydrazine as a partial model for beta-thalassaemia red blood cell hemodynamic properties. Br J Haematol. 2008;140(6):692–700.

    Article  CAS  PubMed  Google Scholar 

  124. Falanga A, Marchetti M, Barbui T. All-trans-retinoic acid and bleeding/thrombosis. Pathophysiol Haemost Thromb. 2003;33(Suppl. 1):19–21.

    Article  PubMed  Google Scholar 

  125. Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T. All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol. 1996;93(2):360–6.

    Article  CAS  PubMed  Google Scholar 

  126. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. J Biol Chem. 2007;282(28):20047–51.

    Article  CAS  PubMed  Google Scholar 

  127. Nishiwaki H, Ogura Y, Miyamoto K, Hiroshiba N, Hamada M, Honda Y. Prednisolone, platelet-activating factor receptor antagonist, or superoxide dismutase reduced leukocyte entrapment induced by interferon alpha in retinal microcirculation. Invest Ophthalmol Vis Sci. 1997;38(5):811–6.

    CAS  PubMed  Google Scholar 

  128. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1998;93(12):2441–4.

    Article  CAS  PubMed  Google Scholar 

  129. Okuse C, Adachi K, Katakura Y, Matsunaga K, Ishii T, Matsumoto N, et al. A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C. J Gastroenterol. 2006;41(12):1231–6.

    Article  CAS  PubMed  Google Scholar 

  130. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Saf. 2001;24(7):491–501.

    Article  CAS  PubMed  Google Scholar 

  131. Lowe GD. Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease. J Intern Med. 2004;256(5):361–74.

    Article  CAS  PubMed  Google Scholar 

  132. Lowe GD, Rumley A, Woodward M, Reid E, Rumley J. Activated protein C resistance and the FV:R506Q mutation in a random population sample: associations with cardiovascular risk factors and coagulation variables. Thromb Haemost. 1999;81(6):918–24.

    CAS  PubMed  Google Scholar 

  133. Sidelmann JJ, Jespersen J, Andersen LF, Skouby SO. Hormone replacement therapy and hypercoagulability: results from the Prospective Collaborative Danish Climacteric Study. BJOG. 2003;110(6):541–7.

    Article  CAS  PubMed  Google Scholar 

  134. Peverill RE. Hormone therapy and venous thromboembolism. Best Pract Res Clin Endocrinol Metab. 2003;17(1):149–64.

    Article  CAS  PubMed  Google Scholar 

  135. Martinelli I, Battaglioli T, Mannucci PM. Pharmacogenetic aspects of the use of oral contraceptives and the risk of thrombosis. Pharmacogenetics. 2003;13(10):589–94.

    Article  PubMed  Google Scholar 

  136. Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, Nicolaes GA, et al. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet. 1999;354(9195):2036–40.

    Article  CAS  PubMed  Google Scholar 

  137. Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, et al. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood. 2004;103(3):927–33.

    Article  CAS  PubMed  Google Scholar 

  138. Mannucci PM, Bettega D, Chantarangkul V, Tripodi A, Sacchini V, Veronesi U. Effect of tamoxifen on measurements of hemostasis in healthy women. Arch Intern Med. 1996;156(16):1806–10.

    Article  CAS  PubMed  Google Scholar 

  139. Pemberton KD, Melissari E, Kakkar VV. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis. Blood Coagul Fibrinolysis. 1993;4(6):935–42.

    CAS  PubMed  Google Scholar 

  140. Glueck CJ, Goldenberg N, Budhani S, Lotner D, Abuchaibe C, Gowda M, et al. Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Transl Res. 2011;158(4):225–34.

    Article  CAS  PubMed  Google Scholar 

  141. Taylor JE, McLaren M, Henderson IS, Belch JJ, Stewart WK. Prothrombotic effect of erythropoietin in dialysis patients. Nephrol Dial Transplant. 1992;7(3):235–9.

    CAS  PubMed  Google Scholar 

  142. Nimmerjahn F, Ravetch JV. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513–33.

    Article  CAS  PubMed  Google Scholar 

  143. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet. 1986;2(8500):217–8.

    Article  CAS  PubMed  Google Scholar 

  144. Marie I, Maurey G, Herve F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol. 2006;155(4):714–21.

    Article  CAS  PubMed  Google Scholar 

  145. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol. 2000;65(1):30–4.

    Article  CAS  PubMed  Google Scholar 

  146. Stratta P, Canavese C, Schinco PC, Montaruli B, Giorda L, Bessone P, et al. Intravenous immunoglobulin contains detectable amounts of antiphospholipid antibodies. Br J Haematol. 1997;96(4):872–3.

    Article  CAS  PubMed  Google Scholar 

  147. Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol. 2007;17(6):546–7.

    PubMed  Google Scholar 

  148. Beinart G, Damon L. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol. 2004;77(4):331–5.

    Article  CAS  PubMed  Google Scholar 

  149. Isacson S. Effect of prednisolone on the coagulation and fibrinolytic systems. Scand J Haematol. 1970;7(3):212–6.

    Article  CAS  PubMed  Google Scholar 

  150. Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol. 1982;68(1):39–42.

    Article  CAS  PubMed  Google Scholar 

  151. Jilma B, Cvitko T, Winter-Fabry A, Petroczi K, Quehenberger P, Blann AD. High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men. Thromb Haemost. 2005;94(4):797–801.

    PubMed  Google Scholar 

  152. Kwaan HC, McFadzean AJ. The inhibition of clot lysis by corticotrophin. Lancet. 1956;270(6908):136–7.

    Article  CAS  PubMed  Google Scholar 

  153. Falanga A, Marchetti M, Evangelista V, Manarini S, Oldani E, Giovanelli S, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999;93(8):2506–14.

    CAS  PubMed  Google Scholar 

  154. LeBlanc R, Roy J, Demers C, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant. 1999;23(10):991–6.

    Article  CAS  PubMed  Google Scholar 

  155. Rella C, Coviello M, Giotta F, Maiello E, Colavito P, Colangelo D, et al. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat. 1996;40(2):151–9.

    Article  CAS  PubMed  Google Scholar 

  156. Rogers JS 2nd, Murgo AJ, Fontana JA, Raich PC. Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988;6(2):276–81.

    PubMed  Google Scholar 

  157. Edwards RL, Klaus M, Matthews E, McCullen C, Bona RD, Rickles FR. Heparin abolishes the chemotherapy-induced increase in plasma fibrinopeptide A levels. Am J Med. 1990;89(1):25–8.

    Article  CAS  PubMed  Google Scholar 

  158. Feffer SE, Carmosino LS, Fox RL. Acquired protein C deficiency in patients with breast cancer receiving cyclophosphamide, methotrexate, and 5-fluorouracil. Cancer. 1989;63(7):1303–7.

    Article  CAS  PubMed  Google Scholar 

  159. Green D. Management of bleeding complications of hematologic malignancies. Semin Thromb Hemost. 2007;33(4):427–34.

    Article  PubMed  Google Scholar 

  160. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005;352(8):777–85.

    Article  CAS  PubMed  Google Scholar 

  161. Maki A, Shirato C, Ohguchi M, Aoki N, Ochiai N, Taguchi S, et al. Mechanism of rethrombosis after thrombolytic therapy: angioscopic findings and investigation of the coagulation system in dogs. Angiology. 1998;49(6):447–53.

    Article  CAS  PubMed  Google Scholar 

  162. Paganelli F, Alessi MC, Morange P, Maixent JM, Levy S, Vague IJ. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery. Thromb Haemost. 1999;82(1):104–8.

    CAS  PubMed  Google Scholar 

  163. Tobu M, Iqbal O, Fareed D, Chatha M, Hoppensteadt D, Bansal V, et al. Erythropoietin-induced thrombosis as a result of increased inflammation and thrombin activatable fibrinolytic inhibitor. Clin Appl Thromb Hemost. 2004;10(3):225–32.

    Article  CAS  PubMed  Google Scholar 

  164. van Giezen JJ, Brakkee JG, Dreteler GH, Bouma BN, Jansen JW. Dexamethasone affects platelet aggregation and fibrinolytic activity in rats at different doses which is reflected by their effect on arterial thrombosis. Blood Coagul Fibrinolysis. 1994;5(2):249–55.

    Article  PubMed  Google Scholar 

  165. Brown JE, Olujohungbe A, Chang J, Ryder WD, Morganstern GR, Chopra R, et al. All-trans retinoic acid (ATRA) and tranexamic acid: a potentially fatal combination in acute promyelocytic leukaemia. Br J Haematol. 2000;110(4):1010–2.

    Article  CAS  PubMed  Google Scholar 

  166. Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood. 2001;98(4):1252–4.

    Article  CAS  PubMed  Google Scholar 

  167. Pouplard C, Iochmann S, Renard B, Herault O, Colombat P, Amiral J, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood. 2001;97(10):3300–2.

    Article  CAS  PubMed  Google Scholar 

  168. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65(12):1642–53.

    Article  CAS  PubMed  Google Scholar 

  169. Yang S, Zhang L. Glucocorticoids and vascular reactivity. Curr Vasc Pharmacol. 2004;2(1):1–12.

    Article  PubMed  Google Scholar 

  170. Vogelzang NJ, Torkelson JL, Kennedy BJ. Hypomagnesemia, renal dysfunction, and Raynaud’s phenomenon in patients treated with cisplatin, vinblastine, and bleomycin. Cancer. 1985;56(12):2765–70.

    Article  CAS  PubMed  Google Scholar 

  171. Turlapaty PD, Altura BM. Magnesium deficiency produces spasms of coronary arteries: relationship to etiology of sudden death ischemic heart disease. Science. 1980;208(4440):198–200.

    Article  CAS  PubMed  Google Scholar 

  172. Sapru H, Theoharides T. Pharmacology (essentials of basic science). 2nd ed. Boston: Little, Brown; 1996.

    Google Scholar 

  173. Cockings JG, Brown M. Ephedrine abuse causing acute myocardial infarction. Med J Aust. 1997;167(4):199–200.

    CAS  PubMed  Google Scholar 

  174. Zaacks SM, Klein L, Tan CD, Rodriguez ER, Leikin JB. Hypersensitivity myocarditis associated with ephedra use. J Toxicol Clin Toxicol. 1999;37(4):485–9.

    Article  CAS  PubMed  Google Scholar 

  175. Vaziri ND, Ritchie C, Brown P, Kaupke J, Atkins K, Barker S, et al. Effect of erythropoietin administration on blood and plasma viscosity in hemodialysis patients. ASAIO Trans. 1989;35(3):505–8.

    Article  CAS  PubMed  Google Scholar 

  176. Spivak JL. Polycythemia vera: myths, mechanisms, and management. Blood. 2002;100(13):4272–90.

    Article  CAS  PubMed  Google Scholar 

  177. Tam BY, Wei K, Rudge JS, Hoffman J, Holash J, Park SK, et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med. 2006;12(7):793–800.

    Article  CAS  PubMed  Google Scholar 

  178. Ishak R, Loh Chooi K. Effect of combined low-dose oral contraceptives on blood viscosity and haematocrit. Malays J Reprod Health. 1991;9(1):5–8.

    CAS  PubMed  Google Scholar 

  179. Alexandrescu DT, Dutcher JP, Hughes JT, Kaplan J, Wiernik PH. Strokes after intravenous gamma globulin: thrombotic phenomenon in patients with risk factors or just coincidence? Am J Hematol. 2005;78(3):216–20.

    Article  PubMed  Google Scholar 

  180. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacol Ther. 2004;102(3):177–93.

    Article  CAS  PubMed  Google Scholar 

  181. Emerson GG, Herndon CN, Sreih AG. Thrombotic complications after intravenous immunoglobulin therapy in two patients. Pharmacotherapy. 2002;22(12):1638–41.

    Article  PubMed  Google Scholar 

  182. Lee YJ, Shin JU, Lee J, Kim K, Kim WS, Ahn JS, et al. A case of deep vein thrombosis and pulmonary thromboembolism after intravenous immunoglobulin therapy. J Korean Med Sci. 2007;22(4):758–61.

    Article  PubMed  Google Scholar 

  183. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res. 2007;19(2):139–48.

    Article  CAS  PubMed  Google Scholar 

  184. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia. 2002;8(2):83–90.

    Article  CAS  PubMed  Google Scholar 

  185. El-Sayed M, Omar A, Lin X. Post-exercise alcohol ingestion perturbs blood haemostasis during recovery. Thromb Res. 2000;99(6):523–30.

    Article  CAS  PubMed  Google Scholar 

  186. El-Sayed MS, Ali N, El-Sayed Ali Z. Interaction between alcohol and exercise: physiological and haematological implications. Sports Med. 2005;35(3):257–69.

    Article  PubMed  Google Scholar 

  187. Baer HJ, Glynn RJ, Hu FB, Hankinson SE, Willett WC, Colditz GA, et al. Risk factors for mortality in the nurses’ health study: a competing risks analysis. Am J Epidemiol. 2011;173(3):319–29.

    Article  PubMed  Google Scholar 

  188. Hansen-Krone IJ, Braekkan SK, Enga KF, Wilsgaard T, Hansen JB. Alcohol consumption, types of alcoholic beverages and risk of venous thromboembolism: the Tromso Study. Thromb Haemost. 2011;106(2):272–8.

    Article  CAS  PubMed  Google Scholar 

  189. Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59(1):20–3.

    Article  CAS  PubMed  Google Scholar 

  190. Pantel J, Schroder J, Eysenbach K, Mundt C. Two cases of deep vein thrombosis associated with a combined paroxetine and zotepine therapy. Pharmacopsychiatry. 1997;30(3):109–11.

    Article  CAS  PubMed  Google Scholar 

  191. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med. 2005;165(22):2677–82.

    Article  PubMed  Google Scholar 

  192. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case–control study. Lancet. 2000;356(9237):1219–23.

    Article  CAS  PubMed  Google Scholar 

  193. Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandala M, et al. Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study. J Transl Med. 2011;9:179.

    Article  CAS  PubMed  Google Scholar 

  194. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, et al. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol. 2000;18(10):2169–78.

    CAS  PubMed  Google Scholar 

  195. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118(4):255–67.

    Article  CAS  PubMed  Google Scholar 

  196. Mano MS, Guimaraes JL, Sutmoller SF, Reiriz AB, Sutmoller CS, Di Leo A. Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. Sao Paulo Med J. 2006;124(6):343–5.

    Article  PubMed  Google Scholar 

  197. Czaykowski PM, Moore MJ, Tannock IF. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160(6 Pt 1):2021–4.

    CAS  PubMed  Google Scholar 

  198. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, et al. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood. 2002;100(4):1168–71.

    Article  CAS  PubMed  Google Scholar 

  199. Kurt M, Shorbagi A, Altundag K, Elkiran T, Gullu I, Kansu E. Possible association between Budd–Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia. Am J Hematol. 2005;80(3):213–5.

    Article  PubMed  Google Scholar 

  200. De Stefano V, Sora F, Rossi E, Chiusolo P, Laurenti L, Fianchi L, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost. 2005;3(9):1985–92.

    Article  PubMed  Google Scholar 

  201. Reddy P, Chow MS. Safety and efficacy of antiestrogens for prevention of breast cancer. Am J Health Syst Pharm. 2000;57(14):1315–22 (quiz 23–5).

    Google Scholar 

  202. Dunkley S, Gaudry L. Thalidomide causes platelet activation, which can be abrogated by aspirin. J Thromb Haemost. 2007;5(6):1323–5.

    Article  CAS  PubMed  Google Scholar 

  203. Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300(19):2277–85.

    Article  CAS  PubMed  Google Scholar 

  204. Heesch CM, Wilhelm CR, Ristich J, Adnane J, Bontempo FA, Wagner WR. Cocaine activates platelets and increases the formation of circulating platelet containing microaggregates in humans. Heart. 2000;83(6):688–95.

    Article  CAS  PubMed  Google Scholar 

  205. Wright NM, Martin M, Goff T, Morgan J, Elworthy R, Ghoneim S. Cocaine and thrombosis: a narrative systematic review of clinical and in-vivo studies. Subst Abuse Treat Prev Policy. 2007;2:27.

    Article  PubMed  Google Scholar 

  206. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. N Engl J Med. 2001;345(5):351–8.

    Article  CAS  PubMed  Google Scholar 

  207. Pislaru S, Pislaru C, Szilard M, Arnout J, Van de Werf F. In vivo effects of contrast media on coronary thrombolysis. J Am Coll Cardiol. 1998;32(4):1102–8.

    Article  CAS  PubMed  Google Scholar 

  208. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007;66(10):1296–304.

    Article  CAS  PubMed  Google Scholar 

  209. Starke RM, Kim GH, Fernandez A, Komotar RJ, Hickman ZL, Otten ML, et al. Impact of a protocol for acute antifibrinolytic therapy on aneurysm rebleeding after subarachnoid hemorrhage. Stroke. 2008;39(9):2617–21.

    Article  CAS  PubMed  Google Scholar 

  210. Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst. 2006;98(10):708–14.

    Article  CAS  PubMed  Google Scholar 

  211. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003;121(4):535–55.

    Article  CAS  PubMed  Google Scholar 

  212. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133–7.

    Article  CAS  PubMed  Google Scholar 

  213. Luna E, Cerezo I, Collado G, Martinez C, Villa J, Macias R, et al. Vascular thrombosis after kidney transplantation: predisposing factors and risk index. Transplant Proc. 2010;42(8):2928–30.

    Article  CAS  PubMed  Google Scholar 

  214. Gangireddy C, Rectenwald JR, Upchurch GR, Wakefield TW, Khuri S, Henderson WG, et al. Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. J Vasc Surg. 2007;45(2):335–41 (discussion 41–2).

    Google Scholar 

  215. Lin HY, Chung CY, Chang CS, Wang ML, Lin JS, Shen MC. Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. J Formos Med Assoc. 2007;106(9):774–8.

    Article  PubMed  Google Scholar 

  216. Copelovitch L, Kaplan BS. The thrombotic microangiopathies. Pediatr Nephrol. 2008;23(10):1761–7.

    Article  PubMed  Google Scholar 

  217. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case–control study. Stroke. 2002;33(6):1465–73.

    Article  CAS  PubMed  Google Scholar 

  218. Zusman RM, Morales A, Glasser DB, Osterloh IH. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83(5A):35C–44C.

    Google Scholar 

  219. Bennett CL, Kiss JE, Weinberg PD, Pinevich AJ, Green D, Kwaan HC, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet. 1998;352(9133):1036–7.

    Article  CAS  PubMed  Google Scholar 

  220. Steinhubl SR, Tan WA, Foody JM, Topol EJ. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting. JAMA. 1999;281(9):806–10.

    Article  CAS  PubMed  Google Scholar 

  221. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This manuscript was prepared without funding and the authors have no relevant conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Hadassah-Hebrew University Medical Center, P.O. Box 12000, 91120, Jerusalem, Israel

    Yuval Ramot

  2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Abraham Nyska

  3. Consultant in Toxicologic Pathology, Timrat, Israel

    Abraham Nyska

  4. Hematology Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

    Galia Spectre

Authors
  1. Yuval Ramot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abraham Nyska
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Galia Spectre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuval Ramot.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ramot, Y., Nyska, A. & Spectre, G. Drug-Induced Thrombosis: An Update. Drug Saf 36, 585–603 (2013). https://doi.org/10.1007/s40264-013-0054-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-013-0054-6

Keywords

Search

Navigation